$OMGA
Omega Therapeutics, Inc.

2023 Form 10-K Financial Statement

#000095017024038094 Filed on March 28, 2024

View on sec.gov

Income Statement

Concept 2023 2022
Revenue $3.094M $2.073M
YoY Change 49.25% 1339.58%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $37.49M $28.74M
YoY Change 30.42% 56.97%
% of Gross Profit
Research & Development $65.87M $80.00M
YoY Change -17.66% 67.13%
% of Gross Profit
Depreciation & Amortization $1.568M $1.600M
YoY Change -2.0% 14.29%
% of Gross Profit
Operating Expenses $103.4M $104.8M
YoY Change -1.42% 58.42%
Operating Profit -$100.3M -$102.8M
YoY Change -2.44% 55.63%
Interest Expense $2.810M $222.0K
YoY Change 1165.77% -75.6%
% of Operating Profit
Other Income/Expense, Net $23.00K $65.00K
YoY Change -64.62% -102.89%
Pretax Income -$97.43M -$102.7M
YoY Change -5.13% 50.41%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$97.43M -$102.7M
YoY Change -5.13% 50.41%
Net Earnings / Revenue -3148.93% -4954.22%
Basic Earnings Per Share -$1.80 -$2.14
Diluted Earnings Per Share -$1.80 -$2.14
COMMON SHARES
Basic Shares Outstanding 54.01M 47.88M
Diluted Shares Outstanding 54.01M 47.88M

Balance Sheet

Concept 2023 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $73.43M $124.7M
YoY Change -41.11% -44.67%
Cash & Equivalents $68.44M $70.62M
Short-Term Investments $4.986M $54.06M
Other Short-Term Assets $9.469M $11.11M
YoY Change -14.8% 223.27%
Inventory
Prepaid Expenses
Receivables $6.131M $618.0K
Other Receivables $855.0K $1.180M
Total Short-Term Assets $89.88M $137.6M
YoY Change -34.67% -39.99%
LONG-TERM ASSETS
Property, Plant & Equipment $114.0M $7.863M
YoY Change 1350.43% 118.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $435.0K $545.0K
YoY Change -20.18% 23.3%
Total Long-Term Assets $114.5M $8.408M
YoY Change 1261.58% 107.76%
TOTAL ASSETS
Total Short-Term Assets $89.88M $137.6M
Total Long-Term Assets $114.5M $8.408M
Total Assets $204.4M $146.0M
YoY Change 39.98% -37.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.620M $3.107M
YoY Change -47.86% 47.32%
Accrued Expenses $18.59M $14.94M
YoY Change 24.44% 66.42%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $4.000M $3.333M
YoY Change 20.01%
Total Short-Term Liabilities $26.81M $21.96M
YoY Change 22.05% 83.29%
LONG-TERM LIABILITIES
Long-Term Debt $14.89M $16.60M
YoY Change -10.35% -16.44%
Other Long-Term Liabilities $104.7M $1.460M
YoY Change 7068.42% 71.16%
Total Long-Term Liabilities $119.5M $18.06M
YoY Change 561.82% -12.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.81M $21.96M
Total Long-Term Liabilities $119.5M $18.06M
Total Liabilities $146.4M $40.03M
YoY Change 265.63% 22.39%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $58.02M $106.0M
YoY Change
Total Liabilities & Shareholders Equity $204.4M $146.0M
YoY Change 39.98% -37.43%

Cashflow Statement

Concept 2023 2022
OPERATING ACTIVITIES
Net Income -$97.43M -$102.7M
YoY Change -5.13% 50.41%
Depreciation, Depletion And Amortization $1.568M $1.600M
YoY Change -2.0% 14.29%
Cash From Operating Activities -$91.51M -$98.52M
YoY Change -7.11% 71.01%
INVESTING ACTIVITIES
Capital Expenditures $2.869M $1.380M
YoY Change 107.9% -5.93%
Acquisitions
YoY Change
Other Investing Activities $50.38M -$16.68M
YoY Change -402.06% -57.16%
Cash From Investing Activities $47.52M -$18.06M
YoY Change -363.1% -55.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $40.49M
YoY Change
Debt Paid & Issued, Net $1.000M
YoY Change
Cash From Financing Activities 41.82M 708.0K
YoY Change 5807.2% -99.73%
NET CHANGE
Cash From Operating Activities -91.51M -98.52M
Cash From Investing Activities 47.52M -18.06M
Cash From Financing Activities 41.82M 708.0K
Net Change In Cash -2.172M -115.9M
YoY Change -98.13% -170.85%
FREE CASH FLOW
Cash From Operating Activities -$91.51M -$98.52M
Capital Expenditures $2.869M $1.380M
Free Cash Flow -$94.38M -$99.90M
YoY Change -5.52% 69.1%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001850838
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2024-09-30
CY2023 us-gaap Operating Loss Carryforwards Expiration Date
OperatingLossCarryforwardsExpirationDate
2036-01-01
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-40657
CY2023 dei Entity Registrant Name
EntityRegistrantName
Omega Therapeutics, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-3247585
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
140 First StreetSuite 501
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02141
CY2023 dei City Area Code
CityAreaCode
617
CY2023 dei Local Phone Number
LocalPhoneNumber
949-4360
CY2023 dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
CY2023 dei Trading Symbol
TradingSymbol
OMGA
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
140200000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
55154985
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Firm
AuditorFirmId
34
CY2023 dei Auditor Name
AuditorName
Deloitte & Touche LLP
CY2023 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68443000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70615000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
4986000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
54063000
CY2023Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
1006000
CY2022Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
618000
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
5125000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10324000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12294000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
89884000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
137590000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5311000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4195000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
108736000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3668000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
341000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
341000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
94000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
204000
CY2023Q4 us-gaap Assets
Assets
204366000
CY2022Q4 us-gaap Assets
Assets
145998000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1620000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3107000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7914000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13841000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1972000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
159000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11300000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1524000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
4000000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
3333000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26806000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21964000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
98243000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1120000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14885000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
16603000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6416000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
340000
CY2023Q4 us-gaap Liabilities
Liabilities
146350000
CY2022Q4 us-gaap Liabilities
Liabilities
40027000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55144982
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55144982
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48072517
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48072517
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
55000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
48000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
392609000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
343608000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-14000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-479000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-334634000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-237206000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
58016000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
105971000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
204366000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
145998000
CY2023 us-gaap Revenues
Revenues
3094000
CY2022 us-gaap Revenues
Revenues
2073000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
77169000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
81167000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26186000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23672000
CY2023 us-gaap Operating Expenses
OperatingExpenses
103355000
CY2022 us-gaap Operating Expenses
OperatingExpenses
104839000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-100261000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-102766000
CY2023 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2810000
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
222000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
23000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-157000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2833000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
65000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-97428000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-102701000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.8
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.8
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.14
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.14
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54010996
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54010996
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47880819
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47880819
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-97428000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-102701000
CY2023 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
465000
CY2022 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-417000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-96963000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-103118000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
200628000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
708000
CY2022 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-417000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7753000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-102701000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
105971000
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
39727000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
488000
CY2023 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
465000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8793000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-97428000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
58016000
CY2023 us-gaap Profit Loss
ProfitLoss
-97428000
CY2022 us-gaap Profit Loss
ProfitLoss
-102701000
CY2023 us-gaap Depreciation
Depreciation
1568000
CY2022 us-gaap Depreciation
Depreciation
1564000
CY2023 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
53000
CY2022 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
67000
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
5203000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
3626000
CY2023 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
192000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1045000
CY2023 omga Change In Fair Value Of Success Fee Obligation
ChangeInFairValueOfSuccessFeeObligation
92000
CY2022 omga Change In Fair Value Of Success Fee Obligation
ChangeInFairValueOfSuccessFeeObligation
13000
CY2023 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
233000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
8793000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
7753000
CY2023 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
388000
CY2022 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
362000
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5125000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1418000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
8592000
CY2023 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-111000
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
3763000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1487000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
985000
CY2023 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-5558000
CY2022 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3233000
CY2023 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1663000
CY2022 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1383000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-91510000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-98515000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2869000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1380000
CY2023 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
650000
CY2023 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
19768000
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
57415000
CY2023 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
69502000
CY2022 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
40735000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
47515000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-18060000
CY2023 omga Proceeds From Equity Offering
ProceedsFromEquityOffering
40000000
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
273000
CY2023 omga Proceeds From Lease Financing
ProceedsFromLeaseFinancing
2623000
CY2023 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1000000
CY2023 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
15000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
488000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
708000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
41823000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
708000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2172000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-115867000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
70956000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
186823000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
68784000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
70956000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68443000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70615000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
341000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
341000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
68784000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
70956000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
1723000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
1263000
CY2023 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
438000
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
13000
CY2023Q4 omga Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
73400000
CY2023 omga Recurring Losses
RecurringLosses
97400000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-91500000
CY2023 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Reclassification</span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company reclassified the related party expenses in the prior year to research and development and general and administrative expenses in the consolidated statements of operations and comprehensive loss to conform to the current year's presentation.</span></p>
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances.</span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the selection of useful lives of property and equipment, the fair value of the success fee obligation, the incremental borrowing rate used in the calculation of lease liabilities, research and development expenses, certain judgments regarding revenue recognition and stock-based compensation. Actual results could differ from these estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Concentrations of credit risk</span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Financial instruments that are potentially subject to significant concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company attempts to minimize the risk related to marketable securities by working with highly rated financial institutions that invest in a broad and diverse range of financial instruments as defined the Company. The Company has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. The Company maintains its funds in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and is designed to limit credit exposure to any single issuer.</span></p>
CY2023 us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Guarantees and indemnifications</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">As permitted under Delaware law, the Company indemnifies its officers, directors, consultants, and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. Through December 31, 2023 and 2022, the Company had </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">t experienced any losses related to these indemnification obligations, and </span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related liabilities were established.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
CY2023 omga Indemnification Obligations Losses
IndemnificationObligationsLosses
0
CY2022 omga Indemnification Obligations Losses
IndemnificationObligationsLosses
0
CY2023 omga Indemnification Obligations Claims Outstanding
IndemnificationObligationsClaimsOutstanding
0
CY2022 omga Indemnification Obligations Claims Outstanding
IndemnificationObligationsClaimsOutstanding
0
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
CY2023 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
CY2023 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2023Q4 omga Prepaid Clinical Expenses
PrepaidClinicalExpenses
5168000
CY2022Q4 omga Prepaid Clinical Expenses
PrepaidClinicalExpenses
5232000
CY2023Q4 omga Prepaid Research And Development
PrepaidResearchAndDevelopment
1609000
CY2022Q4 omga Prepaid Research And Development
PrepaidResearchAndDevelopment
2072000
CY2023Q4 omga Prepaid Facilities
PrepaidFacilities
1242000
CY2022Q4 omga Prepaid Facilities
PrepaidFacilities
1857000
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
855000
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1180000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
716000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1020000
CY2023Q4 omga Prepaid Software
PrepaidSoftware
303000
CY2022Q4 omga Prepaid Software
PrepaidSoftware
157000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
431000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
776000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10324000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12294000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11373000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9609000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6062000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5414000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5311000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4195000
CY2023 us-gaap Depreciation
Depreciation
1600000
CY2022 us-gaap Depreciation
Depreciation
1600000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4482000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4368000
CY2023Q4 omga Research Costs
ResearchCosts
1395000
CY2022Q4 omga Research Costs
ResearchCosts
3876000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
716000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
743000
CY2023Q4 omga Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
547000
CY2022Q4 omga Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
4303000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
147000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
122000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
627000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
429000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7914000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13841000
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
4000000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14900000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
19000000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
20000000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
115000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
64000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
18885000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
19936000
CY2023 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1748000
CY2022 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1229000
CY2023 omga Amortization Of Debt Issuance Costs And Debt Discount
AmortizationOfDebtIssuanceCostsAndDebtDiscount
53000
CY2022 omga Amortization Of Debt Issuance Costs And Debt Discount
AmortizationOfDebtIssuanceCostsAndDebtDiscount
67000
CY2023 us-gaap Interest Expense Debt
InterestExpenseDebt
1801000
CY2022 us-gaap Interest Expense Debt
InterestExpenseDebt
1296000
CY2023 us-gaap Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
147000
CY2022 us-gaap Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
121000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
4000000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
4000000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
4000000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
7000000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
19000000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
15388000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
79839000
CY2021Q4 omga Number Of Phases
NumberOfPhases
2
CY2023Q2 omga Rent Per Square Foot
RentPerSquareFoot
1
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
108700000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
109500000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11300000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
98200000
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
11624000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
3820000
CY2023 us-gaap Variable Lease Cost
VariableLeaseCost
2819000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
1357000
CY2023 us-gaap Lease Cost
LeaseCost
14443000
CY2022 us-gaap Lease Cost
LeaseCost
5177000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P14Y6M
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M18D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.089
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.055
CY2023 omga Schedule Of Supplemental Cash Flow Information Relating To Leases
ScheduleOfSupplementalCashFlowInformationRelatingToLeases
<p style="text-indent:5.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Supplemental cash flow information relating to the Company's leases for the years ended December 31, 2023 and December 31, 2022 were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.16%;"></td> <td style="width:1.5%;"></td> <td style="width:1%;"></td> <td style="width:12.92%;"></td> <td style="width:1%;"></td> <td style="width:1.5%;"></td> <td style="width:1%;"></td> <td style="width:12.92%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31, 2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">December 31, 2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,542</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,637</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Operating lease assets obtained in exchange for lease liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">110,424</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-family:Arial;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-family:Arial;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,393</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:Arial;min-width:fit-content;"> </span></p></td> </tr> </table>
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
8542000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
2637000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
110424000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4393000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
11781000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
11887000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
12213000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
12549000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
12895000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
139504000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
200829000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
91286000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
109543000
CY2023 omga License Maintenances Fees
LicenseMaintenancesFees
200000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8793000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7753000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7465
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7706
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7609
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7762
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.0416
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.0269
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M9D
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-97428000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-102701000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54010996
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54010996
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47880819
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47880819
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.8
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.8
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.14
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.14
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.066
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.071
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.047
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.043
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.009
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.005
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.314
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.32
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.001
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
50762000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
40157000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
16309000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
11013000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1154000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1098000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3329000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1726000
CY2023Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
120000
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
136000
CY2023Q4 omga Irc One Hundred And Seventy Four Capitalization
IrcOneHundredAndSeventyFourCapitalization
32505000
CY2022Q4 omga Irc One Hundred And Seventy Four Capitalization
IrcOneHundredAndSeventyFourCapitalization
20024000
CY2023Q4 omga Asc Eight Hundred And Fourty Two Lease Liability
AscEightHundredAndFourtyTwoLeaseLiability
30198000
CY2022Q4 omga Asc Eight Hundred And Fourty Two Lease Liability
AscEightHundredAndFourtyTwoLeaseLiability
722000
CY2022Q4 omga Deferred Tax Assets Unrealized Gain Loss
DeferredTaxAssetsUnrealizedGainLoss
325000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
134377000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
75201000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
104630000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
74005000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
29747000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1196000
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
12000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
194000
CY2023Q4 omga Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
-29706000
CY2022Q4 omga Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
-1002000
CY2023Q4 omga Deferred Tax Liabilities Unrealized Gain Loss
DeferredTaxLiabilitiesUnrealizedGainLoss
29000
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
29747000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1196000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
30600000
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
187400000
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
180400000
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
187400000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
181900000
CY2023Q3 omga Number Of Shared Space Arrangements
NumberOfSharedSpaceArrangements
3
CY2023 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
share one-third of Sail Bio's 69,867 square feet of leased space at 20 Acorn Park Drive, Cambridge, Massachusetts
omga Net Book Value Of Assets
NetBookValueOfAssets
400000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
200000

Files In Submission

Name View Source Status
0000950170-24-038094-index-headers.html Edgar Link pending
0000950170-24-038094-index.html Edgar Link pending
0000950170-24-038094.txt Edgar Link pending
0000950170-24-038094-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img112225459_0.jpg Edgar Link pending
img112225459_1.jpg Edgar Link pending
img112225459_10.jpg Edgar Link pending
img112225459_11.jpg Edgar Link pending
img112225459_12.jpg Edgar Link pending
img112225459_13.jpg Edgar Link pending
img112225459_14.jpg Edgar Link pending
img112225459_15.jpg Edgar Link pending
img112225459_16.jpg Edgar Link pending
img112225459_17.jpg Edgar Link pending
img112225459_18.jpg Edgar Link pending
img112225459_19.jpg Edgar Link pending
img112225459_2.jpg Edgar Link pending
img112225459_20.jpg Edgar Link pending
img112225459_21.jpg Edgar Link pending
img112225459_3.jpg Edgar Link pending
img112225459_4.jpg Edgar Link pending
img112225459_5.jpg Edgar Link pending
img112225459_6.jpg Edgar Link pending
img112225459_7.jpg Edgar Link pending
img112225459_8.jpg Edgar Link pending
img112225459_9.jpg Edgar Link pending
img245684044_0.jpg Edgar Link pending
img246607565_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
omga-20231231.htm Edgar Link pending
omga-20231231.xsd Edgar Link pending
omga-ex10_12.htm Edgar Link pending
omga-ex10_13.htm Edgar Link pending
omga-ex10_18.htm Edgar Link pending
omga-ex10_20.htm Edgar Link pending
omga-ex10_22.htm Edgar Link pending
omga-ex10_33.htm Edgar Link pending
omga-ex10_9.htm Edgar Link pending
omga-ex23_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
omga-20231231_htm.xml Edgar Link completed
omga-ex31_1.htm Edgar Link pending
omga-ex31_2.htm Edgar Link pending
omga-ex32_1.htm Edgar Link pending
omga-ex32_2.htm Edgar Link pending
omga-ex97.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending